GlassScriptPhysician profile
Thomas Prebet
NPI 1811369507
$41,968.28
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $13K · 2021: $4,988.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,710.00 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $8,000.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $7,353.77 | 2019 | |
| Genentech USA, INC. | $5,705.86 | 2019 | |
| Pfizer INC. | $2,991.15 | 2019 | |
| Abbvie INC. | $2,700.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,640.00 | 2020 | |
| Agios Pharmaceuticals, INC. | $2,340.00 | 2019-2020 | |
| Daiichi Sankyo INC. | $1,527.50 | 2021 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Prebet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.